In a healthcare setting, our patient molecular monitoring solution will deliver earlier, accurate insights for clinicians. This will lead to better patient outcomes and a reduced cost burden on healthcare systems.
For out-patients, the Nutromics platform will provide a new standard of care for patients who would otherwise require extended hospital stays and repeated blood draws.
sepsis related deaths, worldwide
WHO (2020) ‘Global Report on the Epidemiology and Burden of Sepsis: Current evidence, identifying gaps, and future directions.’
drug-resistance related deaths, worldwide
International Coordination Group on Antimicrobial Resistance. (2019). ‘No time to wait: Securing the Future from drug-resistant infections.’
acute kidney injury caused deaths, worldwide
Mehta, R. L., Cerdá, J., Burdmann, E. A., Tonelli, M., García-García, G., Jha, V., and Remuzzi, G. (2015). ‘International Society of Nephrology’s 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology.’
Our first market is Therapeutic Drug Monitoring (TDM) starting with a CMM patch for the antibiotic vancomycin
1 in 5 patients admitted into hospitals in the U.S. get dosed with vancomycin
Vancomycin has a narrow therapeutic range that it must be dosed within to ensure effectiveness
60% of doses of vancomycin are not in the therapeutic range
10-20% of doses of vancomycin are in the nephrotoxic range
Nutromics’ CMM platform will provide clinicians with continuous, and real-time insights into vancomycin concentrations, assisting with dosing and improving patient outcomes
Get in touch
If our vision and work resonates with you and you’d like to be a part of our journey, please get in touch